1. Protective effects of Yerba mate (IIex paraguariensis) on prostate cancer development.
- Author
-
Santiano FE, Fernández MLÁ, Espino M, Zyla LE, Rey L, Gómez SE, Bruna FA, Pistone-Creydt V, Pietrobon E, Pérez Elizalde R, Silva MF, Carón RW, and López Fontana CM
- Subjects
- Male, Mice, Animals, Humans, Mice, Inbred C57BL, Ilex paraguariensis, Drinking Water, Prostatic Neoplasms, Adenocarcinoma
- Abstract
Objectives: Prostate cancer (PCa) is the most common adenocarcinoma in men >50 y of age. It has a long latency period, which provides time for preventive strategies like incorporating healthy eating habits. Yerba mate (YM) intake has been associated with numerous health benefits. Since YM is one of the most popular infusions in Argentina, the of this study was to examine the influence of YM on PCa development., Methods: We carried out an in vivo model of PCa through subcutaneous inoculation of transgenic adenocarcinoma of the mouse prostate-C1 cells in C57BL/6 mice. Subsequently, the animals were divided into two groups: mate (25 mg/mL of YM in drinking water, n = 15), and control (only drinking water, n = 15). We also developed an in vitro model to study the direct effects of YM on three human PCa cell lines: lymph node carcinoma of the prostate (LNCaP), PC-3, and DU-145., Results: Our in vivo model showed that YM intake slightly reduced body weight, increased the latency of tumor appearance (P <0.01), and diminished the tumor volume (P <0.05) compared with the control group. In agreement, the expression of proliferating cell nuclear antigen, and nuclear estrogen receptor α were lower in the tumors of the mate animals (P <0.05). In vitro, YM decreased the viability, proliferation, and adhesion of the three tumor cell lines (P < 0.001) and retarded the migration of LNCaP (P <0.05) and DU-145 (P <0.005), without modifying the migration of PC-3 cells., Conclusions: YM showed anticancer effects in vitro and in vivo and were more effective on the androgen-sensitive cell line (LNCaP)., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF